Bin, T.; Wang, Y.; Tang, J.; Xu, X.-J.; Lin, C.; Lu, B.
Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines 2025, 13, 1845.
https://doi.org/10.3390/biomedicines13081845
AMA Style
Bin T, Wang Y, Tang J, Xu X-J, Lin C, Lu B.
Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines. 2025; 13(8):1845.
https://doi.org/10.3390/biomedicines13081845
Chicago/Turabian Style
Bin, Ting, Ying Wang, Jing Tang, Xiao-Jun Xu, Chao Lin, and Bo Lu.
2025. "Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia" Biomedicines 13, no. 8: 1845.
https://doi.org/10.3390/biomedicines13081845
APA Style
Bin, T., Wang, Y., Tang, J., Xu, X.-J., Lin, C., & Lu, B.
(2025). Prognostic Risk Model of Megakaryocyte–Erythroid Progenitor (MEP) Signature Based on AHSP and MYB in Acute Myeloid Leukemia. Biomedicines, 13(8), 1845.
https://doi.org/10.3390/biomedicines13081845